Objective:
To evaluate the effects of daily aspirin on colorectal cancer (CRC) incidence and mortality, as well as associated risks, including serious adverse events.
Approach:
- Little to no reduction in CRC incidence during the first 15 years of follow-up, which raises concerns about the long-term efficacy of aspirin.
- Increased CRC mortality observed in the first 5 to 10 years in one large trial, suggesting potential acceleration of undetected cancers.
- High-certainty evidence that aspirin increases the risk of serious extracranial hemorrhage, which poses significant clinical concerns.
- Many trials were designed for cardiovascular outcomes, affecting cancer detection and reporting, which may skew results.
- Long-term findings based on observational follow-up introduce bias, particularly from treatment crossover and loss of blinding.
- Limited generalizability due to participant demographics, predominantly older White adults from high-income countries.
Key Findings:
Interpretation:
Current evidence is insufficient to support routine aspirin use for primary CRC prevention, with potential harms outweighing uncertain benefits, necessitating careful consideration in clinical practice.
Limitations:
Conclusion:
Clinical decisions should be individualized, weighing potential cardiovascular benefits against bleeding risks. Future research should focus on nonaspirin NSAIDs, the impact of screening, and the identification of patient subgroups most likely to benefit.
Sources:
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
